|By PR Newswire||
|September 4, 2014 02:00 AM EDT||
BALLERUP, Denmark, September 4, 2014 /PRNewswire/ --
Not for US media
The digital press release with multimedia content can be accessed here: http://www.multivu.com/players/uk/7276254-WCCS-Picato-actinickeratosis/
New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato® (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased. The data also confirm two treatment cycles of Picato® are well tolerated by patients.
These findings are significant as AK is a chronic disease. The presence of underlying sub-clinical (invisible) lesions can lead to recurrence of original AKs and the development of new lesions over time, which normally require repeat treatment. The FIELD Study Repeat followed patients over a one-year-period, confirming both the short and in particular the long-term benefits when treating once or twice of Picato® - with an overall 50% complete clearance of all AK lesions after one year*.
Presenting the data at WCCS today, Professor Claus Garbe, Department of Dermatology, University Hospital Tübingen, Germany and Principal Investigator of the FIELD Repeat Study, commented: "AK is a very common precursor to non-melanoma skin cancer, which requires ongoing treatment. The new data from the FIELD Study Repeat validate Picato® as a well-tolerated field-directed therapy, suitable for the long-term treatment of actinic keratoses, showing an overall high complete clearance rate after one year."
The FIELD Study Repeat is part of the larger international FIELD Study Programme being run by LEO Pharma, designed in partnership with leading clinicians to investigate the potential broader role of Picato® in the management of AK.
Additional data from the FIELD Study Programme was recently published in the Journal of Drugs in Dermatology (JDD) with the long-term results of the FIELD Study 1, investigating the efficacy of Picato® as a field-directed therapy used sequentially following treatment with cryosurgery.
Results show that combining lesion-specific cryosurgery with Picato® field therapy significantly improves the clearance of AK lesions, with an overall 30.5% complete clearance rate, compared to 18.5% with cryosurgery plus vehicle gel over a one year period.
This elevated efficacy results from enhancing the effect of cryosurgery with Picato® on the visible baseline lesions, and from a 'field treatment effect' of Picato® on sub-clinical lesions not visible at baseline (demonstrated by fewer patients experiencing new lesions when treated with Picato® compared to vehicle gel). The data also confirm Picato® field therapy after cryosurgery is well tolerated.
Dr William Hanke, Founder and Medical Director, Dermatologic Surgery, Laser and Skin Center of Indiana, US, and FIELD Study 1 Principal investigator, added:
"The recently published 12 month data from FIELD Study 1 show sustained patient benefits of field treatment with Picato® in combination with cryosurgery. These data are now reinforced with evidence that repeat use of Picato® is efficacious and well tolerated over the same time period. Combined, these studies provide further evidence for the role of field treatment with Picato® in achieving long-term clearance of AK lesions."
Follow @LEOHealthySkin for the latest updates from #WCCS2014.
* Patients treated twice with Picato® or treated once and remained clear at 8w, 26w and 44w, 50% were still clear at 12m (44.0%-56.1%, 95% CI)
NOTES TO EDITORS
1. About Picato® (ingenol mebutate gel)
Picato® is a topical, field-directed therapy which is self-administered by the patient to the affected areas of the skin once a day for two or three consecutive days, depending on the treatment location. Picato® has demonstrated efficacy in clearing actinic keratosis lesions on the face and scalp, as well as on the trunk and extremities, in a large clinical trial programme.
Picato® was approved by the US Food and Drug Administration (FDA) in January 2012; by the Agência Nacional de Vigilância Sanitária (ANVISA) in Brazil in July 2012; by the Therapeutic Goods Administration (TGA) in Australia and the European Commission (EC) in Europe in November 2012, by Health Canada in January 2013 and by the Swiss Agency of Therapeutic Products (Swissmedic) in June 2013.
2. About FIELD Study Repeat
The FIELD Study Repeat involved 450 patients across 5 countries globally, designed to explore the efficacy and tolerability of Picato® repeated treatment within the same area or 'field' on the face or scalp over a 12 month period. For further information please refer to the http://www.clinicaltrials.gov website (identifier: NCT01600014).
3. About the FIELD Study 1
The FIELD Study 1 involved more than 300 patients across 35 US trial sites and explored the efficacy and safety profile of sequential treatment of AK on the face or scalp with cryosurgery followed by Picato®, 0.015% treatment compared with cryosurgery followed by vehicle gel. For further information please refer to the http://www.clinicaltrials.gov website (identifier: NCT01541553).
4. About actinic keratosis (AK)
Actinic keratoses are common skin lesions which are often red and scaly. The majority of lesions are caused by cumulative sun exposure in fair-skinned people. AK is a precursor to non-melanoma skin cancer (NMSC). The number of patients with actinic keratosis is rapidly growing, especially in Europe, the US and Australia. Prevelance currently ranges from 11-25% in the Northern Hemisphere to 40-60% in the Southern Hemisphere.
5. About LEO Pharma
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company. LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. The company has its own sales forces in 61 countries and employs around 4,800 people worldwide. LEO Pharma is headquartered in Denmark and is wholly owned by the LEO Foundation.
For more information about LEO Pharma, visit http://www.leo-pharma.com.
Watch us on YouTube: http://www.youtube.com/leopharmaglobal.
6. Picato® Abrev. SmPC
Contact with the eyes should be avoided. Eye disorders such as eye pain, eyelid oedema and periorbital oedema should be expected to occur after accidental eye exposure of Picato®. Picato® must not be ingested. Administration of Picato® is not recommended until the skin is healed from treatment with any previous medicinal product or surgical treatment and should not be applied to open wounds or damaged skin where the skin barrier is compromised. Picato® should not be used near the eyes, on the inside of the nostrils, on the inside of the ears or on the lips. Local skin responses such as erythema, flaking/scaling, and crusting should be expected to occur after cutaneous application of Picato®. Due to the nature of the disease, excessive exposure to sunlight (including sunlamps and tanning beds) should be avoided or minimised. Lesions clinically atypical for actinic keratosis or suspicious for malignancy should be biopsied to determine appropriate treatment. There are no data from the use of ingenol mebutate gel in pregnant women. Risks to humans receiving cutaneous treatment with ingenol mebutate gel are considered unlikely as Picato® is not absorbed systemically. As a precautionary measure, it is preferable to avoid the use of Picato® during pregnancy. Actinic keratosis is not a condition generally seen within the paediatric population. The safety and efficacy of Picato® for actinic keratosis in patients less than 18 years of age have not been established. Please see full prescribing information available at http://www.leo-pharma.com.
1. Garbe C. Ingenol mebutate gel 0.015% repeat use for multiple actinic keratoses on face and scalp: a 12 month pahse 3 clinical study. Presented at the World Congress on Cancers of the Skin, Edinburgh, Scotland. 4 September 2014
2. LP0041-22 Clinical Study Report EudraCT no. 2011-005018-13 01-Jul-2014 page 1,165
3. Berman B et al. Cutis. 2012; 89:241-50
4. Berman B et al. Journal of drugs in dermatology : JDD. 2014; 13:741-7
5. Lebwohl M et al. N Eng J Med. 2012; 366:1010-9
6. Goldberg L and Mamelak A. Journal of drugs in Dermatology. 2010; 9:1125-32
7. Frost C et al. The British journal of dermatology. 1994; 142:722-6
8. Sober A. Cancer. 1995; 75(2 Suppl):645-50
9. Ulrich M et al. Expert Opinion. 2010; 15:545 - 55
Global Media Contact
Global Communications Manager
LEO Pharma A/S, Denmark
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
Jul. 25, 2016 10:15 PM EDT Reads: 1,662
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Jul. 25, 2016 10:15 PM EDT Reads: 1,917
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, discussed how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved efficienc...
Jul. 25, 2016 10:00 PM EDT Reads: 1,939
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo Silicon Valley Call for Papers is now open.
Jul. 25, 2016 10:00 PM EDT Reads: 2,498
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discussed how businesses can gain an edge over competitors by empowering consumers to take control through IoT. He cited examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He also highlighted how IoT can revitalize and restore outdated business models, making them profitable ...
Jul. 25, 2016 08:30 PM EDT Reads: 1,931
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
Jul. 25, 2016 08:15 PM EDT Reads: 230
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
Jul. 25, 2016 08:00 PM EDT Reads: 1,915
With 15% of enterprises adopting a hybrid IT strategy, you need to set a plan to integrate hybrid cloud throughout your infrastructure. In his session at 18th Cloud Expo, Steven Dreher, Director of Solutions Architecture at Green House Data, discussed how to plan for shifting resource requirements, overcome challenges, and implement hybrid IT alongside your existing data center assets. Highlights included anticipating workload, cost and resource calculations, integrating services on both sides...
Jul. 25, 2016 08:00 PM EDT Reads: 1,965
Big Data engines are powering a lot of service businesses right now. Data is collected from users from wearable technologies, web behaviors, purchase behavior as well as several arbitrary data points we’d never think of. The demand for faster and bigger engines to crunch and serve up the data to services is growing exponentially. You see a LOT of correlation between “Cloud” and “Big Data” but on Big Data and “Hybrid,” where hybrid hosting is the sanest approach to the Big Data Infrastructure pro...
Jul. 25, 2016 07:30 PM EDT Reads: 1,881
In his session at @DevOpsSummit at 19th Cloud Expo, Yoseph Reuveni, Director of Software Engineering at Jet.com, will discuss Jet.com's journey into containerizing Microsoft-based technologies like C# and F# into Docker. He will talk about lessons learned and challenges faced, the Mono framework tryout and how they deployed everything into Azure cloud. Yoseph Reuveni is a technology leader with unique experience developing and running high throughput (over 1M tps) distributed systems with extre...
Jul. 25, 2016 07:15 PM EDT Reads: 2,087
"We are a well-established player in the application life cycle management market and we also have a very strong version control product," stated Flint Brenton, CEO of CollabNet,, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 25, 2016 07:15 PM EDT Reads: 1,794
We all know the latest numbers: Gartner, Inc. forecasts that 6.4 billion connected things will be in use worldwide in 2016, up 30 percent from last year, and will reach 20.8 billion by 2020. We're rapidly approaching a data production of 40 zettabytes a day – more than we can every physically store, and exabytes and yottabytes are just around the corner. For many that’s a good sign, as data has been proven to equal money – IF it’s ingested, integrated, and analyzed fast enough. Without real-ti...
Jul. 25, 2016 07:15 PM EDT Reads: 1,007
In his session at 18th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., and Logan Best, Infrastructure & Network Engineer at Webair, focused on real world deployments of DDoS mitigation strategies in every layer of the network. He gave an overview of methods to prevent these attacks and best practices on how to provide protection in complex cloud platforms. He also outlined what we have found in our experience managing and running thousands of Linux and Unix ...
Jul. 25, 2016 07:15 PM EDT Reads: 1,746
"Operations is sort of the maturation of cloud utilization and the move to the cloud," explained Steve Anderson, Product Manager for BMC’s Cloud Lifecycle Management, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 25, 2016 07:00 PM EDT Reads: 1,881
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Jul. 25, 2016 06:30 PM EDT Reads: 979